Effectiveness

Fosamprenavir (Telzir) is no longer recommended as a component of first-line antiretroviral combinations in British, European or US treatment guidelines. Fosamprenavir was shown to be inferior on some measures to the boosted protease inhibitor lopinavir/ritonavir (Kaletra) in treatment-experienced people and is not recommended for use after the failure of a previous protease inhibitor-containing regimen.1

References

  1. De Jesus E et al. The Context study: efficacy and safety of GW433908 / RTV in PI-experienced subjects with virological failure (24 week results). Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 178, 2003
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.